Ad­u­canum­ab has its ap­proval — now, let cit­i­zen-sci­en­tists come to­geth­er to see if it works

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

Ed­i­tor’s Note: Mad­hav Tham­biset­ty was an ad­vi­sor on the FDA’s Pe­riph­er­al and Cen­tral Ner­vous Sys­tem Drugs ad­vi­so­ry com­mit­tee that vot­ed over­whelm­ing­ly not to rec­om­mend Alzheimer’s drug ad­u­canum­ab’s ap­proval by the FDA. Tham­biset­ty’s views in this op-ed are not re­flec­tions of the po­si­tions of the FDA or the NIH’s Na­tion­al In­sti­tute on Ag­ing, where he is a sec­tion chief of the clin­i­cal and trans­la­tion­al neu­ro­science sec­tion in the lab­o­ra­to­ry of be­hav­ioral neu­ro­science.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN